Pediatric Hematology/Oncology, Department of Pediatrics, University Hospital Tuebingen, Tubingen, Germany.
Swabian Children's Cancer Center, Children's Hospital, Klinikum Augsburg, Augsburg, Germany.
Pediatr Blood Cancer. 2024 Mar;71(3):e30821. doi: 10.1002/pbc.30821. Epub 2023 Dec 26.
Nuclear protein of the testis (NUT) carcinoma (NC) is a rare and highly aggressive tumor defined by the presence of a somatic NUTM1 rearrangement, occurring mainly in adolescents and young adults. We analyzed the clinical and biological features of German pediatric patients (≤18 years) with NC.
This study describes the characteristics and outcome of 11 children with NC registered in the German Registry for Rare Pediatric Tumors (STEP).
Eleven patients with a median age of 13.2 years (range 6.6-17.8) were analyzed. Malignant misdiagnoses were made in three patients. Thoracic/mediastinal tumors were found to be the primary in six patients, head/neck in four cases; one patient had multifocal tumor with an unknown primary. All patients presented with regional lymph node involvement, eight patients (72.7%) with distant metastases. Seven patients underwent surgery, eight radiotherapy with curative intent; polychemotherapy was administered in all patients. Novel treatment strategies including immunotherapy, targeted therapies, and virotherapy were applied in three patients. Median event-free survival and overall survival were 1.5 and 6.5 months, respectively.
Every undifferentiated or poorly differentiated carcinoma should undergo testing for the specific rearrangement of NUTM1, in order to initiate an intense therapeutic regimen as early as possible. As in adults, only few pediatric patients with NC achieve prolonged survival. Thus, novel therapeutic strategies should be included and tested in clinical trials.
睾丸核蛋白(NUT)癌(NC)是一种罕见且高度侵袭性的肿瘤,其特征为存在体细胞 NUTM1 重排,主要发生在青少年和年轻成年人中。我们分析了德国儿科患者(≤18 岁)中 NC 的临床和生物学特征。
本研究描述了在德国罕见儿科肿瘤登记处(STEP)中登记的 11 例 NC 儿童患者的特征和结局。
分析了 11 例中位年龄为 13.2 岁(范围 6.6-17.8)的患者。3 例患者存在恶性误诊。6 例患者的原发性肿瘤位于胸部/纵隔,4 例位于头颈部;1 例患者有多发性肿瘤,原发灶未知。所有患者均存在区域淋巴结受累,8 例(72.7%)存在远处转移。7 例患者接受了手术,8 例接受了根治性放疗;所有患者均接受了化疗。3 例患者采用了新的治疗策略,包括免疫疗法、靶向治疗和病毒治疗。中位无事件生存和总生存时间分别为 1.5 个月和 6.5 个月。
为了尽早启动强化治疗方案,所有未分化或低分化癌均应进行 NUTM1 特异性重排检测。与成人一样,只有少数 NC 儿科患者能获得长期生存。因此,应在临床试验中纳入并测试新的治疗策略。